Bayer (ETR:BAYN) named strategy chief Werner Baumann to replace Marijn Dekkers as CEO today, prompting some industry watchers to speculate that there’s more deal-making ahead for the German firm’s non-pharma markets. Baumann, who’s slated to succeed Dekkers May 1, joined Bayer in 1988 and made a name for himself with the successful integration of rival drugmaker […]
Positron fights creditors’ bid for involuntary bankruptcy
Cardiac imaging specialist Positron Corp. (OTC:POSC) is fighting a bid for involuntary bankruptcy issued by 3 parties who are alleging to be creditors of the company, according to an SEC filing posted last week. The Chicago-based company said it plans to oppose the petition and move to dismiss the filing, according to the SEC filing. Positron […]
ViewRay tables $52m IPO | Medtech Wall Street news for the week of April 13, 2015
Positron conducts 1-for-400 reverse stock split
Cardiac imaging specialist Positron Corp. (OTC:POSC) said it conducted a 1-for-400 reverse stock split yesterday.
MRI Interventions taps Intuitive Surgical’s Grillo for CEO | Personnel Moves
iCad soars on Medicare reimbursement nod | Wall Street Beat
Positron Corp. touts regulatory wins in U.S., U.K.
Nuclear imaging device maker Positron Corp. (OTC:POSC) touted a pair of wins coming from partnerships.
Late last week the Crown Point, Ind.-based company announced FDA approval for its new cfrQuant coronary flow reserve quantification software, which was developed by the University of Texas Health Science Center in Houston under the guidance of Positron’s Dr. Lance Gould.
Biomet’s Q3 losses widen on modest top-line growth | Earnings Roundup
Third-quarter losses mounted for orthopedic device giant Biomet Inc. as its top line enjoyed only modest growth.
Warsaw, Ind.-based Biomet posted losses of $16.5 million, on sales of $708.9 million, during the 3 months ended Feb. 29, 2012, compared with losses of $11.6 million, on sales of $678 million, during the same period last year.
Adjusted for 1-time expenses, the company’s net income for Q3 came to $55.1 million, compared to adjusted profits of $212.8 million during Q3 2011.
BD to deal labware biz to Corning for $730M | Wall Street Beat
Becton Dickinson & Co. (NYSE:BDX) said it agreed to sell its BD Biosciences – Discovery Labware unit to Corning Inc. (NYSE:GLW) for about $730 million in cash.
Boston Scientific launches Pluromed’s BackStop kidney stone treatment | Wall Street Beat
Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.
Medtronic lands FDA clearance, plans launch for next-gen CRM lead | Regulatory Roundup
Medtronic Inc. (NYSE:MDT) landed FDA clearance for its DF4 high-voltage right ventricular lead for use with implantable cardiac rhythm management devices.
The DF4, which builds on Medtronic’s Sprint Quattro lead, aims to help simplify the implantation process with a redesigned port and by providing visual confirmation of the lead’s connection to the device.
MassDevice Network
@MassDevice
LinkedIn
YouTube